BCG006 / Biocytogen, Lepu Med - LARVOL DELTA

Biocytogen and CtM Bio Achieve Milestone Progress in Co-Developing a TCR-mimic Antibody-based Multi-Specific T Cell Engager Targeting WT1/HLA-A02 (Businesswire) - "Biocytogen Pharmaceuticals (Beijing) Co., Ltd...today jointly announce that the development of a tri-specific T cell engager for an intracellular target achieved milestone progress. In just one year since the start of the collaboration, the companies have identified a WT1/HLA-A02-specific T cell engager (WT1xCD3x4-1BB tri-specific antibody) with outstanding preclinical anti-tumor activities for both hematological malignancies and solid tumors. The incorporation of the T co-stimulatory signal for WT1-targeting T cell engager further gives it the best-in-class properties and first-in-class potential. Its preclinical data has been accepted for presentation at the upcoming 2024 AACR annual meeting."

Preclinical • Hematological Malignancies • Solid Tumor